Does visceral fat include neck fat? This is a common question, and the short answer is no — but the relationship between neck fat and visceral fat is more nuanced than it first appears. Visceral fat is stored deep within the abdominal cavity, surrounding vital organs, whereas neck fat is subcutaneous. However, research suggests that neck circumference may serve as a useful indirect marker of overall adiposity and metabolic risk, including elevated visceral fat. This article explains the key differences, associated health risks, and NHS-recommended strategies for reducing both types of fat.

What Is Visceral Fat and Where Does It Accumulate?

Visceral fat accumulates deep within the abdominal cavity, surrounding internal organs such as the liver and pancreas. It is metabolically active and is assessed clinically using waist circumference thresholds per NICE CG189.

Visceral fat is a specific type of body fat stored deep within the abdominal cavity, surrounding vital internal organs such as the liver, pancreas, intestines, and kidneys. Unlike fat stored just beneath the skin, visceral fat is metabolically active, meaning it releases hormones and inflammatory chemicals that can directly influence organ function and systemic health. It is sometimes described as 'active fat' because of its role in metabolic processes, though this is a lay term rather than a formal clinical classification.

Visceral fat accumulates primarily in the abdominal region, which is why a large waist circumference is used in UK clinical practice as a proxy for elevated visceral fat levels (NICE CG189). It is important to understand that visceral fat is not visible from the outside — a person may appear slim yet still carry a clinically significant amount of visceral fat around their internal organs, a pattern sometimes described as being 'TOFI' (thin outside, fat inside).

Factors associated with visceral fat accumulation include:

• Poor diet, particularly high in refined carbohydrates, sugar, and saturated fats

• Physical inactivity

• Chronic stress and elevated cortisol levels (an association rather than a proven direct cause)

• Excess alcohol consumption

• Hormonal changes, particularly those associated with the menopause (an association supported by observational evidence)

• Genetic predisposition

It is worth noting that people from South Asian, Chinese, Black African, and Middle Eastern backgrounds may carry a higher metabolic risk at lower waist circumference and BMI values than White European populations; NICE CG189 provides ethnicity-specific guidance on this.

Visceral fat is distinct from subcutaneous fat, which sits just beneath the skin and can be felt or pinched. Both types of fat exist throughout the body, but their health implications differ considerably. Understanding this distinction is essential when considering whether fat in specific areas — such as the neck — falls into the visceral category.

Is Neck Fat Considered Visceral or Subcutaneous Fat?

Neck fat is subcutaneous fat, not visceral fat, as it lies beneath the skin rather than surrounding internal organs. However, increased neck circumference is associated with higher visceral fat levels and greater cardiometabolic risk.

To answer the question directly: neck fat is not visceral fat. Visceral fat, by definition, is confined to the abdominal cavity and surrounds internal organs. Neck fat, by contrast, is classified as subcutaneous fat — fat that lies beneath the skin but above the muscle layer. This distinction is anatomically important, as the neck does not contain the organ-surrounding fat depots found in the abdomen.

That said, research does suggest that neck circumference may serve as a useful indirect marker of overall adiposity and metabolic risk. Studies have found associations between increased neck circumference and higher levels of visceral fat, insulin resistance, and cardiometabolic risk factors. This means that while neck fat itself is subcutaneous, its presence may reflect broader patterns of fat distribution that include elevated visceral fat. This is an associative relationship; a direct causal link has not been established.

Neck fat can accumulate for several reasons, including:

• General weight gain and overall increased body fat percentage

• Obstructive sleep apnoea (OSA): there is a well-recognised bidirectional association between increased neck circumference and OSA, largely mediated through overall adiposity and upper airway narrowing, rather than neck fat being a direct cause or consequence in isolation

• Cushing's syndrome, a hormonal condition causing fat redistribution, including to the neck and upper back (sometimes called a 'buffalo hump')

• Certain medicines, such as long-term corticosteroids, which can cause similar fat redistribution patterns

If you notice unexplained or rapidly increasing fat around the neck or upper back, it is advisable to speak with your GP, as this may warrant investigation for underlying hormonal or metabolic conditions. In most cases, however, neck fat reflects general excess body fat rather than a standalone clinical concern.

Health Risks Associated With Excess Neck and Visceral Fat

Excess visceral fat is strongly linked to type 2 diabetes, cardiovascular disease, and MASLD, while excess neck fat is most notably associated with obstructive sleep apnoea. Both are meaningful clinical indicators of broader metabolic dysfunction.

Excess visceral fat is strongly associated with a range of serious health conditions. Because visceral fat is metabolically active, it releases pro-inflammatory cytokines and free fatty acids directly into the portal circulation, which can impair liver function and contribute to systemic inflammation. High levels of central and abdominal adiposity are linked to an increased risk of:

• Type 2 diabetes

• Cardiovascular disease, including heart attack and stroke

• Metabolic-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease (NAFLD) — see NICE NG49 for UK assessment and management guidance

• Certain cancers, including colorectal and breast cancer — Cancer Research UK and the World Cancer Research Fund (WCRF) UK provide evidence on the links between obesity and abdominal adiposity and cancer risk

• Metabolic syndrome — a cluster of conditions including high blood pressure, raised blood glucose, and abnormal cholesterol levels

Excess neck fat, while subcutaneous in nature, carries its own set of health implications. One of the most clinically significant is its association with obstructive sleep apnoea (OSA). Increased fat around the neck can narrow the upper airway during sleep, leading to repeated episodes of breathing interruption. OSA is associated with daytime fatigue, poor concentration, hypertension, and increased cardiovascular risk. The STOP-Bang screening tool, widely used in UK clinical practice, includes a neck circumference threshold of ≥40 cm (for both men and women) as one of its risk criteria. The British Thoracic Society also recognises neck circumference as a relevant risk factor for OSA in adults.

Furthermore, a larger neck circumference has been independently associated with insulin resistance and dyslipidaemia in several population studies, suggesting it may reflect broader metabolic dysfunction beyond simple subcutaneous fat accumulation. Taken together, both visceral and neck fat should be considered meaningful clinical indicators, and their presence warrants a holistic assessment of metabolic health rather than a purely cosmetic evaluation.

How to Measure and Monitor Visceral Fat in the UK

Waist circumference is the primary NHS clinical proxy for visceral fat, with NICE CG189 thresholds of ≥94 cm for men and ≥80 cm for women. MRI and CT are the gold standard but are reserved for research settings.

Accurately measuring visceral fat is not straightforward, as it cannot be assessed by simply looking at or touching the body. The gold standard for measuring visceral fat is MRI (magnetic resonance imaging) or CT (computed tomography) scanning, both of which can precisely quantify fat depots around internal organs. However, these methods are expensive and are not used routinely in NHS clinical practice solely for this purpose; their use for visceral fat quantification is largely confined to research settings.

In everyday NHS clinical settings, the following practical tools are used as proxies for visceral fat (NICE CG189):

• Waist circumference: NICE recommends action thresholds of ≥94 cm (37 inches) for men and ≥80 cm (31.5 inches) for women, with higher-risk thresholds at ≥102 cm for men and ≥88 cm for women. Lower thresholds apply to people from South Asian, Chinese, and some other ethnic backgrounds — refer to NICE CG189 for ethnicity-specific values

• Waist-to-hip ratio (WHR): A ratio above 0.90 in men and 0.85 in women indicates central obesity (WHO guidance)

• Waist-to-height ratio (WtHR): A ratio above 0.5 is considered a risk indicator across most adult populations

• BMI (body mass index, kg/m²): While widely used, BMI does not distinguish between fat types or distribution and should be interpreted alongside waist measurements. Ethnicity-specific lower thresholds apply for some groups per NICE CG189

Some consumer-grade bioelectrical impedance scales claim to estimate visceral fat levels, though their accuracy varies considerably and they should not be used as a substitute for clinical assessment. DEXA (dual-energy X-ray absorptiometry) scanning can provide detailed body composition analysis but is not routinely commissioned on the NHS for adiposity assessment; it is more commonly available in research or private settings.

If you are concerned about your visceral fat levels, your GP can assess your risk using waist circumference, BMI, blood pressure, and blood tests including HbA1c (the preferred test for diabetes risk assessment in UK primary care) and a fasting lipid profile. These investigations align with NICE guidance on cardiovascular risk assessment (NICE NG238) and can help identify whether further intervention is needed.

NHS-Recommended Ways to Reduce Visceral and Neck Fat

Visceral fat responds well to a combination of aerobic exercise, resistance training, and dietary changes aligned with the NHS Eatwell Guide. Spot reduction of neck fat is not evidence-based; it reduces as part of overall body fat loss.

The encouraging news is that visceral fat is highly responsive to lifestyle modification — often more so than subcutaneous fat. The NHS and NICE both emphasise that a combination of dietary change, increased physical activity, and behavioural support is the most effective approach to reducing visceral fat and improving overall metabolic health.

Dietary recommendations include:

• Reducing intake of ultra-processed foods, refined sugars, and sugary drinks

• Following a Mediterranean-style diet or the principles of the NHS Eatwell Guide, rich in vegetables, wholegrains, lean proteins, legumes, and healthy fats such as olive oil

• Limiting alcohol consumption in line with NHS guidelines (no more than 14 units per week, spread across at least three days)

• Avoiding crash diets, which can lead to muscle loss and rebound weight gain

Physical activity is particularly effective at targeting visceral fat. The UK Chief Medical Officers' Physical Activity Guidelines recommend:

• At least 150 minutes of moderate-intensity aerobic activity per week (e.g., brisk walking, cycling, swimming)

• Strength or resistance training at least twice per week, which helps preserve muscle mass and improve insulin sensitivity

• Reducing prolonged sitting, even alongside regular exercise

For neck fat specifically, there is no evidence that spot reduction — targeting fat loss in one area through localised exercise — is effective. Neck fat will reduce as part of overall body fat loss achieved through the strategies above. If neck fat is associated with a condition such as OSA or Cushing's syndrome, treating the underlying cause is essential.

For individuals who require additional support, NICE CG189 sets out criteria for pharmacological and surgical options:

• Orlistat is typically considered for adults with a BMI ≥30 kg/m² (or ≥28 kg/m² with weight-related risk factors), subject to dietary adherence and a review at 12 weeks (continuation requires ≥5% weight loss per BNF criteria)

• Semaglutide 2.4 mg (Wegovy), a GLP-1 receptor agonist, is available via specialist NHS weight-management services only under NICE TA875, for adults with a BMI ≥35 kg/m² and at least one weight-related comorbidity, or in selected cases with a BMI of 30–34.9 kg/m²; lower BMI thresholds (reduced by approximately 2.5 kg/m²) apply to people from certain ethnic groups

• Bariatric surgery may be considered for eligible individuals as outlined in NICE CG189

Always consult your GP before starting any weight management programme, particularly if you have existing health conditions. Your GP can refer you to appropriate NHS weight management services and advise on the most suitable options for your circumstances.

Frequently Asked Questions